MGCD0103: A New Drug for Colon Cancer
Author Information
Author(s): Sikandar Shaheen, Dizon Diana, Shen Xiling, Li Zuomei, Besterman Jeffery, Lipkin Steven M.
Primary Institution: University of California, Irvine
Hypothesis
Can the class I HDAC inhibitor MGCD0103 effectively target colon cancer initiating cells (CCIC) and non-CCIC cells?
Conclusion
MGCD0103 shows significant anti-tumor activity against both CCIC and non-CCIC colon cancer cells.
Supporting Evidence
- MGCD0103 effectively inhibits CCIC proliferation and clonogenicity.
- MGCD0103 shows anti-tumor activity in xenograft models.
- DKK-1 expression is significantly upregulated by MGCD0103 treatment.
Takeaway
A new drug called MGCD0103 can help stop the growth of bad cells in colon cancer, making it a promising treatment.
Methodology
The study involved screening various drugs for their effects on CCIC and non-CCIC cells, followed by in vitro and in vivo testing of MGCD0103.
Potential Biases
Potential bias due to funding from Methylgene, the company that provided MGCD0103.
Limitations
The study primarily focused on specific cell lines and may not fully represent all colon cancer types.
Statistical Information
P-Value
0.7–1.0μM
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website